Predicting therapy resistance in castration-resistant prostate cancer with circulating tumor DNA
Predicting therapy resistance in castration-resistant prostate cancer with circulating tumor DNA
批准号:
371318
负责人:
Wyatt Alexander W
金额:
$37.62万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-09-01 至 2020-09-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The standard of care therapies for advanced prostate cancer, abiraterone and enzalutamide, are not effective in 20-40% of patients. We currently are unable to recognize this subset of patients up-front, which means they are inevitably treated with a drug
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
-
批准号:451909
-
项目类别:Operating Grants
-
资助金额:$61.3万
-
财政年份:2021
-
负责人:Wyatt Alexander W
-
依托单位:
Genomic dissection of de novo metastatic prostate cancer prior to treatment
-
批准号:445330
-
项目类别:Operating Grants
-
资助金额:$53.5万
-
财政年份:2021
-
负责人:Wyatt Alexander W
-
依托单位:
Circulating tumour DNA as a precision oncology tool for metastatic bladder cancer
-
批准号:373906
-
项目类别:Salary Programs
-
资助金额:$10.56万
-
财政年份:2017
-
负责人:Wyatt Alexander W
-
依托单位:
海外基金